AI Article Synopsis

  • The study explores the transplantation of a liver from an HCV-seropositive donor who achieved sustained virologic response (SVR) into an HCV-seronegative recipient, highlighting no reactivation of HCV despite significant immunosuppression.
  • The patient, a 21-year-old male, underwent severe graft rejection and intense immunosuppression but remained HCV RNA-negative for 8 months post-transplant, indicating a successful outcome.
  • This case suggests that achieving SVR in donors might indicate a more definitive cure for HCV, as the recipient did not experience HCV reactivation even under extreme medical conditions.

Article Abstract

Background: The goal of treating chronic hepatitis C virus (HCV) infection is sustained virologic response (SVR). There is concern that despite achieving SVR, replication-competent HCV may be sequestered at low levels within the liver and could theoretically reactivate with immunosuppression. We report transplantation of a HCV-seropositive liver donor, who achieved SVR, into a seronegative patient without HCV reactivation despite profound immunosuppression.

Method: Retrospective chart review.

Results: We present a 21-year-old male who was HCV seronegative and received a liver transplant from a donor who had been treated for HCV and achieved SVR. The liver recipient, despite developing severe acute graft rejection and undergoing intense immunosuppression with T cell-depleting antibodies, did not become HCV RNA-positive with a follow up period of 8 months. The recipient was HCV seronegative before transplant, but became HCV seropositive immediately posttransplant. The antibodies were undetectable after 97 days, in keeping with a passive antibody transmission or B lymphocyte transmission with the graft.

Conclusions: To the best of our knowledge, this is the first reported case of an HCV seropositive liver allograft transplanted into an HCV-negative recipient who subsequently received intense immunosuppression. This case, therefore, is an encouraging and novel step in liver transplantation, and demonstrates that SVR may be closer to a true "cure" of HCV in the donor population and that, even in circumstances of very potent immunosuppression in the recipient, this SVR is sustained.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912017PMC
http://dx.doi.org/10.1097/TXD.0000000000000763DOI Listing

Publication Analysis

Top Keywords

hcv
11
liver allograft
8
hepatitis virus
8
sustained virologic
8
virologic response
8
acute graft
8
graft rejection
8
achieved svr
8
hcv seronegative
8
intense immunosuppression
8

Similar Publications

SLAMF7 defines subsets of human effector CD8 T cells.

Sci Rep

December 2024

Singapore Immunology Network (SIgN), Agency for Science Technology and Research (A*STAR), Immunos Building, 8A Biomedical Grove, Biopolis, Republic of Singapore.

Long-term control of viral replication relies on the efficient differentiation of memory T cells into effector T cells during secondary immune responses. Recent findings have identified T cell precursors for both memory and exhausted T cells, suggesting the existence of progenitor-like effector T cells. These cells can persist without antigenic challenge but expand and acquire effector functions upon recall immune responses.

View Article and Find Full Text PDF

Lactoferrin (Lf) is a naturally occurring glycoprotein known for its antiviral and antibacterial properties and is present in various physiological fluids. Numerous studies have demonstrated its antiviral effectiveness against multiple viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus (IFV), herpes simplex virus (HSV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). Lf, a vital component of the mucosal defense system, plays a crucial role in inhibiting viral infection by binding to both host cells and viral particles, such as the Hepatitis C virus (HCV).

View Article and Find Full Text PDF

HLA Class I (A and B) Allele Polymorphism in a Moroccan Population Infected with Hepatitis C Virus.

Curr Issues Mol Biol

December 2024

Laboratory of Immunology and Human Leukocyte Antigen, Center of Clinical Research, Mohammed VI University Hospital, Marrakech 40080, Morocco.

Hepatitis C virus (HCV) infection is one of the major health burdens worldwide. Its course depends on the virus itself and the host's immune responses. The latter are conditioned by immunogenetic factors, in particular human leukocyte antigens (HLAs), whose role in determining the outcome of infection varies according to populations and ethnic groups.

View Article and Find Full Text PDF

Background: Major adverse cardiovascular events (MACEs) may contribute to the high morbidity in people with four-class drug-resistant HIV (4DR-PWH).

Objectives: To explore the probability of MACEs in 4DR-PWH compared with non-4DR controls.

Methods: This was a retrospective, propensity score-matched cohort study on 4DR-PWH (cases) and non-4DR-PWH (controls), on ART, without previous MACEs.

View Article and Find Full Text PDF

Residual HCV-RNA and Elevated Platelet-to-Lymphocyte Ratio Predict Poor Long-Term Outcomes in Patients with Chronic Hepatitis C After Treatment.

Infect Dis Ther

December 2024

Division of Tropical Medicine and Epidemiology, Division of Tropical and Parasitic Diseases, Institute of Maritime and Tropical Medicine, Faculty of Health Sciences, Medical University of Gdansk, Powstania Styczniowego 9B, 81-519, Gdynia, Poland.

Introduction: Despite achieving sustained viral response (SVR) after treatment with direct-acting antivirals (DAAs), the risk of liver disease progression and extrahepatic complications in chronic hepatitis C (CHC) remains. We aimed to determine the role of residual HCV-RNA in peripheral blood mononuclear cells (PBMCs), a condition known as occult hepatitis C (OCI), and systemic inflammatory markers as predictors of long-term outcomes in patients treated with DAAs.

Methods: We followed 42 patients treated with DAAs with OCI status determined after therapy, for a median of 6.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!